FrancophonIA/ELRC3.0 huggingface dataset:
English: The study compared these two medicines when used to boost the effects of atazanavir, given in combination with another standard HIV-1 medicine containing emtricitabine and tenofovir.
Maltese: L-istudju qabbel dawn iż-żewġ mediċini meta użati biex isaħħu l-effetti ta' atanzanavir, meta jingħata ma' mediċina tal-HIV-1 standard oħra li fiha emtricitabine u tenofovir.
English: The most common side effects with Tybost (which may affect more than 1 in 10 people) when given with atazanavir are ocular icterus (yellowing of the whites of the eyes), nausea (feeling sick) and jaundice (yellowing of the skin and eyes).
Maltese: L-effetti sekondarji l-aktar komuni b'Tybost (li jistgħu jaffettwaw lil aktar minn persuna 1 minn kull 10) meta jingħata ma' atazanavir huma ikterus okulari (sfurija tal-abjad tal-għajnejn), nawżja (dardir) u suffejra (sfurija tal-ġilda u l-għajnejn).
English: The main measure of effectiveness was based on the reduction in viral load (the amount of virus found in the blood): patients who attained a viral load of less than 50 HIV-1 RNA copies/ml after 48 weeks of treatment were considered to have responded to treatment.
Maltese: Ilkejl ewlieni tal-effikaċja kien ibbażat fuq it-tnaqqis tat-tagħbija virali (l-ammont ta' vajrus misjub fiddemm): il-pazjenti li kisbu tagħbija virali ta' anqas minn 50 kopja/ml ta' HIV-1 RNA wara 48 ġimgħa ta' kura kienu kkunsidrati bħala li rrispondew għall-kura.
English: How is Tybost used?
Maltese: Kif jaħdem Tybost?
English: Treatment with Tybost and atazanavir or darunavir does not cure HIV-1 infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS, when combined with other standard HIV-1 medicines.
Maltese: Il-kura b'Tybost u atazanavir jew darunavir ma tikkurax l-infezzjoni tal-HIV-1 jew l-AIDS, iżda tista' tittardja l-ħsara fis-sistema immunitarja u l-iżvilupp ta' infezzjonijiet u mard assoċjat mal-AIDS, meta jintuża flimkien ma' mediċini tal-HIV-1 standard oħrajn.
English: By blocking CYP3A, Tybost slows down the rate at which atazanavir and darunavir are broken down, thereby prolonging the length of time they act in the body.
Maltese: Dan jispjega kif l-Aġenzija vvalutat il-mediċina biex tirrakkomanda l-awtorizzazzjoni fl-UE u l-kondizzjonijiet ta' użu.
English: When the enzyme is blocked, the virus cannot reproduce normally, which slows down the spread of infection.
Maltese: Meta l-enzima tiġi mblokkata, ilvajrus ma jistax jiġi riprodott normalment, u dan inaqqas it-tifrix tal-infezzjoni.
English: Tybost does not treat HIV directly but is given to boost the effects of atazanavir or darunavir, which are used with other standard medicines to treat HIV-1.
Maltese: Tybost ma jikkurax l-HIV direttament iżda jingħata biex isaħħaħ l-effetti ta' atazanavir jew darunavir, li jintużaw ma' mediċini standard oħra biex jikkuraw l-HIV-1.
English: It is not intended to provide practical advice on how to use Tybost.
Maltese: Dan mhux intiż biex jipprovdi konsultazzjoni prattika fuq l-użu ta' Tybost.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Onept IL-2 on 3/05/2013.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Oncept IL-2 fit-3/05/2013.
English: Oncept-IL2 is produced by a method known as ‘recombinant DNA technology': it contains viruses that have received a gene (DNA), which makes them able to produce IL-2.
Maltese: Oncept-IL2 jiġi prodott b'metodu magħruf bħala ‘teknoloġija rikombinanti tad-DNA': fih vajruses li jkunu rċevew ġene (DNA) li jagħmilhom kapaċi jipproduċu IL-2.
English: Oncept IL-2 is a veterinary medicine that contains the active substance feline interleukin-2 recombinant canarypox virus (vCP1338).
Maltese: Oncept IL-2 huwa mediċina veterinarja li fiha s-sustanza attiva vajrus tal-ġidri tal-kanarin (razza vCP1338) rikombinanti għall-interlewkina-2 felina.
English: The active substance in Oncept IL-2 is a ‘carrier' canarypox virus that contains the gene to produce the protein feline interleukin-2 (IL-2).
Maltese: Is-sustanza attiva f'Oncept IL-2 hija ‘trasportatur' tal-vajrus tal-kanarin li fiha l-ġene li jipproduċi l-proteina interlewkina-2 felina (IL-2).
English: Side effects that may be seen with Oncept IL-2 treatment are short lived apathy (lack of responsiveness) and hyperthermia (increased body temperature above 39.5 °C from the normal value of 38 - 38.5 °C).
Maltese: Effetti sekondarji li jistgħu jidhru bil-kura b'Oncept IL-2 huma apatija (nuqqas ta' reazzjoni) li ddum tul perjodu qasir u ipertermja (żieda fit-temperatura tal-ġisem 'l fuq minn 39.5
English: It usually disappears spontaneously within one week.
Maltese: Ġeneralment din tisparixxi b'mod spontanju fi żmien ġimgħa.
English: Oncept IL-2 reduced the risk of relapse in the period from six months after the start of treatment by approximately 56% after one year and 65% after two years.
Maltese: Oncept IL-2 naqqas ir-riskju li t-tumur jreġa' lura fil-perjodu inkwistjoni minn sitt xhur wara l-bidu talkura b'madwar 56% wara sena u b'65% wara sentejn.
English: Oncept-IL2 is an immunomodulating agent, which means that it affects the activity of the immune system (the body's natural defences).
Maltese: Oncept-IL2 huwa aġent immunomodulanti, li jfisser li jaffettwa l-attività tas-sistema immunitarja (iddifiżi naturali tal-ġisem).
English: A moderate reaction at the injection site may occur that involves signs of pain when the area is touched, swelling and scratching.
Maltese: Jista' jkun hemm reazzjoni moderata fis-sit tal-injezzjoni li tinvolvi sinjali ta' uġigħ meta l-erja tintmiss, nefħa u ħakk.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Oncept IL-2 exceed the risks for the approved indication and recommended that Oncept IL-2 be given a marketing authorisation.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu Veterinarju (CVMP) ikkonkluda li l-benefiċċji ta' Oncept IL-2 jegħlbu r-riskju għall-indikazzjoni approvata u għaldaqstant irrakkomanda li Oncept IL-2 jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: The studies showed that in cats treated with Oncept IL-2 the tumours took longer to come back (over 730 days based on the mid value of the range) compared with control cats (287 days).
Maltese: L-istudji wrew li fi qtates li rċevew kura b'Oncept IL-2 it-tumuri damu aktar biex reġgħu ġew lura (aktar minn 730 jum abbażi tal-valur tan-nofs tal-medda) apparagun mal-qtates ta' kontroll (287 jum).
English: It is available as a lyophilisate (freeze dried pellet) and solvent (water for injections) that are made up into a suspension for injection.
Maltese: Jiġi f'lijofilizzat (pellet imnixxef iffriżat) u solvent (ilma għal injezzjonijiet) li jiġu magħmula f'sospensjoni għal injezzjoni.
English: Oncept IL-2 was studied in two field studies involving 71 cats which had spontaneously developed fibrosarcoma that had not spread to other parts of the body.
Maltese: Oncept IL-2 ġie studjat f'żewġ studji fuq il-post li fih ħadu sehem 71 qattus li kienu żviluppaw fibrosarkoma b'mod spontanju li ma tkunx infirxet lejn partijiet oħra tal-ġisem.
English: The benefit/risk balance may be found in the scientific discussion module of this EPAR.
Maltese: Il-bilanċ benefiċċji/riskji jinstab fil-modulu tad-diskussjoni xjentifika ta' dan l-EPAR.
English: Feline interleukin-2 recombinant canary pox virus
Maltese: Vajrus tar-razza tal-kanarin rikombinanti għall-interlewkina-2 felina
English: What is the risk associated with Oncept IL-2?
Maltese: X'riskji huma assoċjati ma' Oncept IL-2 ?
English: The two studies compared a total of 48 cats treated with Oncept IL-2 with 23 control cats that just received surgery and radiotherapy.
Maltese: Iż-żewġ studji qabblu total ta' 48 qattus li rċevew kura b'Oncept IL-2 ma' 23 qattus ta' kontroll li kienu għadhom kif kellhom kirurġija u radjuterapija.
English: Oncept IL-2 is used when the size of the tumour is between 2 and 5 cm in diameter and there is no spread of the cancer to other parts of the body.
Maltese: Oncept IL-2 jintuża meta d-daqs tat-tumur ikollu dijametru ta' 2-5 cm u l-kanċer ma jkunx laħaq infirex lejn partijiet oħra tal-ġisem.
English: Other information about Oncept IL-2:
Maltese: Tagħrif ieħor dwar Oncept IL-2 :
English: Oncept IL-2 is used to treat cats with fibrosarcoma, a type of aggressive tumour which affects the soft tissues.
Maltese: Oncept IL-2 jintuża fil-kura ta' qtates bil-fibrosarkoma, li huwa tip ta' tumur aggressiv li jaffettwa ttessuti rotob.
English: What is Oncept IL-2?
Maltese: X'inhu Oncept IL-2 ?
English: How has Oncept IL-2 been studied?
Maltese: Kif ġie studjat Oncept IL-2 ?
English: It is used in combination with surgery and radiotherapy to reduce the risk of and delay the tumour coming back.
Maltese: Jintuża flimkien mal-kirurġija u r-radjuterapija biex inaqqas ir-riskju li t-tumur jiġi lura u biex itawwal iż-żmien ta' dal-proċess.
English: This summary was last updated in March 2013.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'Marzu 2013.
English: Avenida Río de Janeiro, 60 - 66, planta 13 08016 Barcelona (España)
Maltese: Río de Janeiro, 60 - 66, planta 13 08016 Barcelona (España)
English: Tengströminkatu 8, 20360 Turku
Maltese: Tengströminkatu 8, 20360
English: The elimination half-life (t½) is 40-50 minutes.
Maltese: Il-half life ta' eliminazzjoni (t½) hija ta' 40-50 minuta.
English: Ltd, Αγίου Νικολάου 8, 1055 Λευκωσία, Κύπρος, τηλ.
Maltese: Αγίου Νικολάου 8, 1055 Λευκωσία,
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance:
Maltese: U KWANTITATTIVA Sustanza Attiva :
English: VIAL/MULTI PACKAGE
Maltese: VJALA / PAKKETT MULTIPLU
English: VETOQUINOL SA Magny-Vernois 70200 Lure
Maltese: VETOQUINOL SA Magny-Vernois 70200
English: Lifepharma (Z.A.M.)
Maltese: Lifepharma (Z.A.M.) Ltd,
English: ROUTE(S) OF ADMINISTRATION Dogs: IM, IV
Maltese: MOD TA' AMMINISTRAZZJONI Klieb: IM, IV
English: Luxembourg/Luxemburg VETOQUINOL SA Magny-Vernois 70200 Lure
Maltese: Luxembourg/Luxemburg VETOQUINOL SA Magny-Vernois 70200
English: Sintra Business Park, Nº7, Edifício 1 - Escritório 2K Zona Industrial de Abrunheira 2710-089 Sintra
Maltese: Sintra Business Park, Nº7, Edifício 1 - Escritório 2K
English: List of excipients:
Maltese: Lista ta' ingredjenti:
English: Shelf life after first opening: 3 months at 25°C.
Maltese: Jekk tiftaħ jibqa' tajjeb għal: 3 xhur f'25°C.
English: EXPIRY DATE EXP: month/year
Maltese: DATA TA' SKADENZA EXP: xahar/sena
English: Metabolites are excreted mainly in the urine (51% of the dose), and to a lesser extent in the faeces.
Maltese: Il-metaboliti jiġu eliminati laktar fl-urina (51% tad-doża) u xi ftit anqas fl-ippurgar.
English: Sedation lasts for at least 120 minutes post administration and analgesia lasts for at least 90 minutes.
Maltese: L-irqad idum mill-anqas 120 minuta wara l-amministrazzjoni u s-serħan milluġiġħ idum mill-anqas 90 minuta.
English: Cats: IM
Maltese: IM
English: Cat Weight
Maltese: Klieb Piż
English: The mean half-life of elimination of dexmedetomidine increased to 1.6 h and the total exposure (AUC) increased by 50%.
Maltese: Il-medja tal-half life ta' eliminazzjoni ta' dexmedetomidine żdiedet għal 1.6 siegħat u l-ammont totali (AUC) żdied b'50%.
English: Ελλάδα
Maltese: IL-PROVVISTA U L
English: QUANTITY OF THE ACTIVE SUBSTANCE(S) 0.1 mg/ml dexmedetomidine hydrochloride
Maltese: TAS-SUSTANZA ATTIVA / SUSTANZI ATTIVI 0.1 mg/ml dexmedetomidine hydrochloride
English: QUANTITY OF THE ACTIVE SUBSTANCE(S) 0.5 mg/ml dexmedetomidine hydrochloride
Maltese: TAS-SUSTANZA ATTIVA / SUSTANZI ATTIVI 0.5 mg/ml dexmedetomidine hydrochloride
English: Intravenously: up to 375 micrograms/square metre body surface area Intramuscularly: up to 500 micrograms/square metre body surface area
Maltese: Fil-vina: sa 375 mikrogrammi/metru kwadru tal-wiċċ tal-ġisem Fil-muskolu: sa 500 mikrogrammi/metru kwadru tal-wiċċ tal-ġisem
English: INDICATIONS
Maltese: INDIKAZZJONI
English: Dog
Maltese: UŻU
English: 0.1 mg dexmedetomidine hydrochloride equivalent to 0.08 mg dexmedetomidine
Maltese: 0.1 mg dexmedetomidine hydrochloride ekwivalenti għal 0.08 mg dexmedetomidine
English: After a 40 micrograms/kg bw intramuscular dose the Cmax is 17 nanograms/ml.
Maltese: Wara doża ta' 40 mikrogrammi/kg piż fil-muskolu, is-Cmax hi ta' 17 nanogrammi/ml.
English: PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: psycholeptic, ATCvet code: QN05CM18.
Maltese: Grupp Farmako-terapewtiku: psikoleptiku, Kodiċi ATC veterinarja:
English: The premedication dose of dexmedetomidine is 125 - 375 micrograms/square metre body surface area, administered 20 minutes prior to induction for procedures requiring anaesthesia.
Maltese: Id-doża ta' premedikazzjoni ta' dexmedetomidine hija ta' 125 - 375 mikrogrammi/metru kwadru tal-wiċċ tal-ġisem, mogħtija 20 minuta qabel jinbdew proċeduri li jeħtieġu l-anestesija.
English: CATS:
Maltese: QTATES:
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Active substance:
Maltese: U INGREDJENT(I) OĦRA Sustanza Attiva:
English: ΕΛΑΝΚΟ ΕΛΛΑΣ Α.Ε.Β.Ε 335 Μεσογείων,15231 Χαλάνδρι,Αττική-Ελλάς
Maltese: Χαλάνδρι,Αττική-Ελλάς
English: Advice to doctors: Dexdomitor is an α2-adrenoreceptor agonist, symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia.
Maltese: Dexdomitor huwa α2-adrenoreceptor agonist, sintomi wara assorbiment jistgħu jinvolvu effetti kliniċi inkluż sedazzjoni dipendenti fuq id-doża, dipressjoni respiratorja, bradikardja, pressjoni għolja b'mod anormali, ħalq xott, u ipergliċemija.
English: ANNEX II
Maltese: ΕΛΛΑΣ Α.Ε.Β.Ε
English: The apparent volume of distribution (Vd) is 2.2 L/kg and the elimination half-life (t½) is one hour.
Maltese: Il-volum ta' distribuzzjoni (Vd) jidher li huwa ta' 2.2 L/kg u l-half life ta' eliminazzjoni (t½) hija ta' siegħa.
English: The product is not intended for repeat injections.
Maltese: Il-prodott mhuwiex maħsub għal injezzjonijiet ripetuti.
English: Package size: 15 ml and 10 x 15 ml
Maltese: Daqs tal-pakkett: 15 ml, 10 x 15 ml
English: Cats: intramuscular use
Maltese: Qtates: injezzjoni fil-muskolu
English: Package size: 10 ml and 10 x 10 ml
Maltese: Daqs tal-pakkett: 10 ml, 10 x 10 ml
English: Weight
Maltese: Lott
English: Dexmedetomidine 500 micrograms/m2
Maltese: Dexmedetomidine 500 mikrogrammi/m2
English: After a 40 micrograms/kg bw intramuscular dose the Cmax is 17 ng/ml.
Maltese: Wara doża ta' 40 mikrogrammi/kg piż fil-muskolu, is-Cmax hi ta' 17 ng/ml.
English: Anaesthesia can be induced 10 minutes after premedication by intramuscular administration of a target dose of 5 mg ketamine/ kg bw or by intravenous administration of propofol to effect.
Maltese: L-anestesija tista' tinbeda 10 minuta wara l-premedikazzjoni b'doża ta' 5 mg ketamina /kg piż filmuskolu jew b'amministazzjoni ta' propofol fil-vina skont l-effett.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT DEXDOMITOR 0.1 mg/ml solution for injection
Maltese: VETERINARJU DEXDOMITOR 0.1 mg/ml soluzzjoni għal injezzjoni
English: NAME OF THE VETERINARY MEDICINAL PRODUCT DEXDOMITOR 0.5 mg/ml solution for injection
Maltese: VETERINARJU DEXDOMITOR 0.5 mg/ml soluzzjoni għal injezzjoni
English: Dexmedetomidine 40 mcg/kg intramuscularly
Maltese: Dexmedetomidine 40 mcg/kg fil-muskolu
English: MARKETING AUTHORISATION NUMBER(S) EU/2/02/033/001-002
Maltese: NUMRU(I) TA' L-AWTORIZZAZZJONI TAL-KUMMERĊ EU/2/02/033/001-002
English: All known metabolites lack pharmacological activity.
Maltese: Il-metaboliti kollha magħrufa m'għandhomx attivita farmakoloġika.
English: Major biotransformations in the dog include hydroxylation, glucuronic acid conjugation and Nmethylation in the liver.
Maltese: Bio-trasformazzjonijiet maġġuri fil-kelb jinkludu idrossilazzjoni, konjugazzjoni mal-aċidu glukoroniku u N-methylation fil-fwied.
English: Intramuscular dosing at 40 micrograms/kg (followed by ketamine or propofol) frequently resulted in sinus bradycardia and sinus arrhythmia, occasionally resulted in 1st degree atrioventricular block, and rarely resulted in supraventricular premature depolarizations, atrial bigeminy, sinus pauses, 2nd degree atrioventricular block, or escape beats/rhythms.
Maltese: Doża ta' 40 mikrogrammi/kg fil-muskolu (segwita minn ketamina jew propofol) spiss wasslet għal sinus bradycardia u sinus arrhythmia, kultant wasslet għal AV block ta' l-ewwel grad, u rari wasslet għal dipolariżazzjonijiet supraventrikolari prematuri, atrial bigeminy, pawżi tas-sinus, AV block tat-tieni grad, jew battiti/ritmi maħrubin.
English: Intramuscular dosing at 40 mcg/kg (followed by ketamine or propofol) frequently resulted in sinus bradycardia and sinus arrhythmia, occasionally resulted in 1st degree atrioventricular block, and rarely resulted in supraventricular premature depolarizations, atrial bigeminy, sinus pauses, 2nd degree atrioventricular block, or escape beats/rhythms.
Maltese: Doża ta' 40 mcg/kg fil-muskolu (segwita minn ketamina jew propofol) spiss wasslet għal sinus bradycardia u sinus arrhythmia, kultant wasslet għal AV block ta' l-ewwel grad, u rari wasslet għal dipolariżazzjonijiet supraventrikolari prematuri, atrial bigeminy, pawżi tas-sinus, AV block tat-tieni grad, jew battiti/ritmi maħrubin.
English: When administering in conjunction with butorphanol (0.1 mg/kg) for deep sedation and analgesia, the intramuscular dose of dexmedetomidine is 300 micrograms/square metre body surface area.
Maltese: Meta tuża flimkien ma' butorfanol (0.1 mg/kg) għal irqad fil-fond u serħan mill-uġiġħ, id-doża ta' dexmedetomidine fil-muskolu hija 300 mikrogrammi/metru kwadru tal-wiċċ tal-ġisem.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/02/033/003-004
Maltese: NUMRU(I) TA' L-AWTORIZZAZZJONI TAL-KUMMERĊ EU/2/02/033/003-004
English: The peak sedative and analgesic effects are reached within 30 minutes after administration.
Maltese: Atipamezole m'għandhiex tingħata qabel 30 minuta mill-amministarzzjoni tal-ketamina.
English: For deep sedation and analgesia with butorphanol
Maltese: ANNESS I KARATTERISTIĊI
English: Dexmedetomidine 40 micrograms/kg intramuscularly
Maltese: Dexmedetomidine 40 mikrogrammi/kg fil-muskolu
English: When dexmedetomidine and butorphanol are used concomitantly in dogs, bradypnoea, tachypnoea, an irregular respiratory pattern (20-30 sec apnoea followed by several rapid breaths), hypoxaemia, muscle twitch or tremor or paddling, excitation, hypersalivation, retching, vomiting, urination, skin erythema, a sudden arousal, or prolonged sedation may occur.
Maltese: Meta dexmedetomidine u butarfanol jintużaw flimkien fil-klieb, jista' jkun hemm nifs bil-mod jew mgħaġġel, xejra respiratorja irregolari (20-30 sekonda qtugħ ta' nifs, segwiti minn ħafna nifsijiet mgħaġġla), nuqqas ta' ossiġnu fid-demm, ġibda jew rogħda fil-muskoli, qdif bir-riġlejn, eċċitament, produzzjoni għolja ta' bżieq, tqalligħ, remettar, tluq ta' l-urina, eritima tal-ġilda, tistembaħ f'daqqa jew irqad fit-tul.
English: DOGS: In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate dose of atipamezole is 10 times the initial dose of dexmedetomidine (micrograms/ kg bw or micrograms/ square meter body surface area).
Maltese: F'każi ta' doża eċċessiva, jew fejn l-effetti ta' dexmedetomidine jistgħu ikunu ta' theddida għal ħajja, id-doża xierqa ta' atipamezole hija 10 darbiet aktar mid-doża inizjali ta' dexmedetomidine (mikrogrammi/ kg piż jew mikrogrammi/ metru kwadru tal-wiċċ tal-ġisem).
English: The dose volume of atipamezole at the concentration of 5 mg/ml equals one- tenth (1/10) the volume of Dexdomitor 0.1 mg/ml that was given to the cat.
Maltese: Il-volum ta' doża ta' atipamezole b'konċentrazzjoni ta' 5 mg/ml huwa daqs wieħed f'għaxra (1/10) tal-volum ta' Dexdomitor 0.1 mg/ml li ingħata lil qattus.
English: When dexmedetomidine and butorphanol are used concomitantly in dogs bradypnoea, tachypnoea, an irregular respiratory pattern (20-30 sec apnoea followed by several rapid breaths), hypoxaemia, muscle twitch or tremor or paddling, excitation, hypersalivation, retching, vomiting, urination, skin erythema, a sudden arousal, or prolonged sedation may occur.
Maltese: Meta dexmedetomidine u butarfanol jintużaw flimkien fil-klieb, jista' jkun hemm nifs bil-mod jew mgħaġġel, xejra respiratorja irregolari (20-30 sekonda qtugħ ta' nifs, segwiti minn ħafna nifsijiet mgħaġġla), nuqqas ta' ossiġnu fid-demm, ġibda jew rogħda fil-muskoli, qdif bir-riġlejn, eċċitament, produzzjoni għolja ta' bżieq, tqalligħ, remettar, tluq ta' l-urina, eritima tal-ġilda, stembieħ f'daqqa jew irqad fit-tul.
English: CATS: In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate antagonist is atipamezole, administered by intramuscular injection, at the following dose: 5 times the initial dose dexmedetomidine in micrograms/kg bw.
Maltese: F'każi ta' doża eċċessiva, jew fejn l-effetti ta' dexmedetomidine jistgħu ikunu ta' theddida għal ħajja, l-antagonista xieraq huwa atipamezole, amministrat b'injezzjoni fil-muskolu bid-doża kif ġej: 5 darbiet aktar mid-doża inizjali ta' dexmedetomidine f'mikrogrammi/kg piż.
English: For higher weight ranges, use DEXDOMITOR 0.5 mg/ml and its dosing tables.
Maltese: Għal piżijiet ogħla, uża DEXDOMITOR 0.5 mg/ml u t-tabelli ta' dożaġġ tiegħu.
English: The bioavailability of dexmedetomidine is 60% and the apparent volume of distribution (Vd) is 0.9 L/kg.
Maltese: Il-bioavilibilita fil-ġisem ta' dexmedetomidine hija ta' 60% u lvolum ta' distribuzzjoni (Vd) jidher li huwa ta' 0.9
English: Package size: 15 ml, 10 x 15 ml.
Maltese: PIŻ, VOLUM JEW NUMRU TA' DOŻI 15 ml, 10 x 15 ml
English: Dogs: After an intramuscular dose of 50 micrograms/kg a maximum concentration in plasma of about 12 ng/ml is reached after 0.6 hours.
Maltese: Wara doża fil-muskolu ta' 50 mikrogrammi/kg, l-ogħla konċentrazzjoni fil-plażma, ta' madwar 12 ng/ml tintlaħaq wara 0.6 ta' siegħa.
English: Sedation may be reversed with atipamezole.
Maltese: Jista' jkun hemm ċpar fil-kornea tal-qtates waqt li traqqad.
English: Dogs: After an intramuscular dose of 50 micrograms/kg a maximum concentration in plasma of about 12 nanograms/ml is reached after 0.6 hours.
Maltese: Wara doża fil-muskolu ta' 50 mikrogrammi/kg, l-ogħla konċentrazzjoni fil-plażma, ta' madwar 12 nanogrammi/ml tintlaħaq wara 0.6 ta' siegħa.
English: A dose of 10 mg ketamine/ kg used concurrently with 40 micrograms dexmedetomidine/ kg may cause tachycardia.
Maltese: Doża ta' 10 mg ketamina/kg flimkien ma' 40 mikrogrammi dexmedetomidine /kg tista' twassal biex ilqalb tħabbat b'rata mgħaġġla.
English: A dose of 10 mg ketamine/kg used concurrently with 40 micrograms dexmedetomidine/ kg may cause tachycardia.
Maltese: Doża ta' 10 mg ketamina /kg flimkien ma' 40 mikrogrammi dexmedetomidine /kg tista' twassal biex ilqalb tħabbat b'rata mgħaġġla.
English: PACKAGE LEAFLET DEXDOMITOR 0.1 mg/ml solution for injection
Maltese: DEXDOMITOR 0.1 mg/ml soluzzjoni għal injezzjoni
English: PACKAGE LEAFLET DEXDOMITOR 0.5 mg/ml solution for injection
Maltese: DEXDOMITOR 0.5 mg/ml soluzzjoni għal injezzjoni
English: The dose volume of atipamezole at the concentration of 5 mg/ml is one fifth (1/5) of the dose volume of Dexdomitor 0.1 mg/ml that was given to the dog, regardless of route of administration of Dexdomitor.
Maltese: atipamezole b'konċentrazzjoni ta' 5 mg/ml huwa wieħed f'ħamsa (1/5) tal-volum ta' doża ta' Dexdomitor 0.1 mg/ml li ingħata lill-kelb, ikun xi jkun il-mod ta' amministrazzjoni ta' Dexdomitor.
English: After concurrent exposure to a triple (3X) overdose of dexmedetomidine and 15 mg ketamine/ kg, atipamezole can be administered at the recommended dose level for reversal of effects induced by dexmedetomidine.
Maltese: Wara li tingħata doża eċċessiva ta' dexmedetomidine bi tlett darbiet (3X), flimkien ma' 15 mg ketamina/ kg, atimpamezole jista' tingħata fil-livell ta' doża rakkomandat biex treġġa' lura l-effetti ta' dexmedetomidine.
English: Dexdomitor, butorphanol and/or ketamine can be mixed in the same syringe as they have been shown to be pharmaceutically compatible.
Maltese: Dexdomitor, butorphanol u/jew ketamine jistgħu jitħalltu fl-istess siringa minħabba li ntwerew li huma farmakoloġikament kompatibbli.